Full-metal jacket technique using second-generation drug-eluting stent: clinical and angiographic follow-up in 2 years
- 14 February 2019
- journal article
- research article
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- Vol. 34 (4) , 305-311
Abstract
The aims of this study are to evaluate the efficacy of percutaneous coronary intervention (PCI) using full-metal jacket (FMJ) with second-generation drug-eluting stents (DES). A single-center, non-randomized, retrospective study was performed from May 2005 to February 2014 at Miyazaki Medical Association Hospital, Japan. PCI using FMJ with DES was performed to treat 240 very long lesions (> 60 mm) in 240 patients. Subjects were divided into a first-generation or second-generation DES group. The primary endpoint was the incidence of major adverse cardiac events (MACE) at 2 years. MACE included all-cause death, myocardial infarction (MI), cerebrovascular event, and target vessel revascularization. The secondary endpoint was binary restenosis (> 50% stenosis) assessed by angiography at 1 year of follow-up. Second-generation DES were implanted to treat 121 lesions, and the first-generation DES were implanted to treat 119 lesions. Since 35 patients were lost to follow-up, the final analysis included 102 patients with second-generation DES and 103 with first-generation DES. At the 2-year follow-up, the incidence of MACE was significantly less in the second-generation DES group (9.8% vs. 20.4%, p = 0.03). The incidence of binary restenosis at 1 year was also significantly lower in the second-generation DES group (6.7% vs 29.1%, p < 0.01). When PCI was performed using FMJ with DES to treat very long lesion, the angiographic and clinical outcomes were better with second-generation than first-generation DES.Keywords
This publication has 21 references indexed in Scilit:
- Comparison of mid-term clinical outcomes between “complete full-metal jacket strategy” versus “incomplete full-metal jacket strategy” for diffuse right coronary artery stenosis with drug-eluting stentsJournal of Cardiology, 2016
- Extended follow-up following “full-metal jacket” percutaneous coronary interventions with drug-eluting stentsCatheterization and Cardiovascular Interventions, 2014
- Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting StentsJACC: Cardiovascular Interventions, 2011
- Long-Term Outcomes After the Percutaneous Treatment of Drug-Eluting Stent RestenosisJACC: Cardiovascular Interventions, 2011
- An Integrated TAXUS IV, V, and VI Intravascular Ultrasound Analysis of the Predictors of Edge Restenosis After Bare Metal or Paclitaxel-Eluting StentsThe American Journal of Cardiology, 2009
- Clinical and Angiographic Outcomes After Placement of Multiple Overlapping Drug-Eluting Stents in Diffuse Coronary LesionsThe American Journal of Cardiology, 2006
- Clinical Efficacy of Polymer-Based Paclitaxel-Eluting Stents in the Treatment of Complex, Long Coronary Artery Lesions From a Multicenter, Randomized TrialCirculation, 2005
- “Full metal jacket” (stented length ≥64 mm) using drug-eluting stents for de novo coronary artery lesionsAmerican Heart Journal, 2005
- Comparison of Thrombosis and Restenosis Risk from Stent Length of Sirolimus-Eluting Stents Versus Bare Metal StentsThe American Journal of Cardiology, 2005
- Drug-eluting stent thrombosisJACC, 2005